Renal function, atherothrombosis extent, and outcomes in high-risk patients

American Heart Journal

Volumn 158, Issue 1, 2009, Pages

  Dumaine, Raphaelle L ^a   Montalescot, Gilles ^a   Steg, Ph Gabriel ^b   Ohman, E Magnus ^c   Eagle, Kim ^d   Bhatt, Deepak L ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; AMPUTATION; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT; PRIORITY JOURNAL; REGISTER; REVASCULARIZATION; RISK FACTOR; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 67049164746     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.05.011     Document Type: Article

References (19)

1. Lindner A., Charra B., Sherrard D.J., et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290 (1974) 697-701
2. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41 (2003) 47-55
3. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
4. Dumaine R., Collet J.P., Tanguy M.L., et al. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol 94 (2004) 1543-1547
5. Gibson C.M., Dumaine R.L., Gelfand E.V., et al. Association of glomerular filtration rate on presentation with subsequent mortality in non ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 25 (2004) 1998-2005
6. Santopinto J.J., Fox K.A., Goldberg R.J., et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 89 (2003) 1003-1008
7. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
8. Ohman E.M., Bhatt D.L., Steg P.G., et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 151 (2006) 786.e1-786.e10
9. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
10. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005) 2089-2100
11. Berger A.K., Duval S., and Krumholz H.M. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42 (2003) 201-208
12. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291 (2004) 451-459
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
14. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
15. Tonelli M., Moye L., Sacks F.M., et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
16. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
17. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
18. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45 (2005) S1-S153
19. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 (2003) S207-S210